Apertura Gene Therapy Shares CNS Capsid Tech for Research
The platform enables scalable production of AAV capsids designed to improve targeted drug delivery in the brain and spinal cord.
Updated on Oct. 28, 2026 in Biotech
Live Poll
Should companies share proprietary technology to help accelerate medical research and development?
Apertura Gene Therapy is providing researchers with access to its TfR1 CapX adeno-associated virus (AAV) capsid, a delivery vehicle engineered for the central nervous system. The company enables this through material transfer agreements and advisory support, leveraging manufacturing processes that scale to 500-liter clinical batches.
Why it matters
Broad access to specialized capsids is intended to accelerate the development of gene therapies targeting the brain and spinal cord. By standardizing manufacturing and sharing these tools, the company aims to lower the barrier for academic and industry labs working on neurological treatments.
Apertura Gene Therapy has demonstrated the ability to produce clinical-grade batches of its TfR1 CapX capsid at a scale of 500 liters. The process uses standard unit operations and commercially available reagents to maintain consistent quality for bespoke viral vectors.
The players
Apertura Gene Therapy
A developer of specialized viral vector technologies and AAV capsids designed for CNS-targeted genetic medicines.
Jorge Santiago-Ortiz
A presenter representing Apertura Gene Therapy who detailed the company’s capsid development strategies at the Bioprocessing Summit.
The details
The TfR1 CapX capsid is a modified adeno-associated virus (AAV) — a non-pathogenic virus used to deliver therapeutic genetic material into cells. To ensure the capsid is ready for clinical manufacturing, Apertura integrates design-for-manufacturability principles early in development. The company also adapts standard analytical techniques to characterize the specific properties of these custom-engineered capsids, ensuring they meet regulatory standards.
Timeline
October 2026: Jorge Santiago-Ortiz presented on engineered capsids at the Bioprocessing Summit in Boston.
The Tech Race
Apertura Gene Therapy is positioning its platform as a scalable alternative to custom capsid development, which has historically been a significant bottleneck in gene therapy. This effort follows a pattern of industrialization at events like the Bioprocessing Summit, where companies seek to transition from artisanal, low-yield methods to robust, large-scale bioprocessing.
Academic and commercial researchers can now access the TfR1 CapX technology through Material Transfer Agreements for their nonclinical studies. This access includes consultative support on regulatory strategies to assist developers in navigating the path from lab-scale experiments to clinical-grade production.
The takeaway
The move toward open-access capsid platforms may reduce the time required to bring central nervous system therapies into clinical trials. Developers should watch for future technical documentation regarding the performance of TfR1 CapX in specific disease models to assess its efficacy against emerging competitive platforms.
Further reading
For more on the latest developments in genetic medicine delivery, visit the Biotech section.
Source note: This article includes information reported by GEN - Genetic Engineering and Biotechnology News.
Live Poll
Should companies share proprietary technology to help accelerate medical research and development?
